The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin. The new pill, developed by Vertex Pharmaceuticals, is intended for short-term pain relief following surgery or injury, the Associated Press reported. While it provides a long-awaited alternative to opioids and over-the-counter painkillers like ibuprofen, research suggests its effectiveness is modest compared to standard opioid treatments. Unlike opioids, which bind to brain receptors to reduce pain but often lead to dependence and addiction, Journavx works differently. The medication blocks specific proteins that trigger pain signals before they reach the brain. “In trying to develop medicines that don’t have the addictive risks of opioid medicines, a key factor is working to block pain signaling before it gets to the brain,” Dr. David Altshuler, Vertex’s executive vice president and chief scientific officer, previously told the Associated Press. Studies of more than 870 patients who took Journavx after foot and abdominal surgery showed that the drug provided more relief than a placebo but was not more effective than a common opioid-acetaminophen combination pill. “It’s not a slam dunk on effectiveness,” Michael Schuh of the Mayo Clinic, a pharmacist who was not involved in the research, told the Associated Press. “But it is a slam dunk in that it’s a very different… read on > read on >

















